Interpharm Revenue from 2010 to 2026
| IPAH Stock | USD 0 0.00 0.00% |
Interpharm Holdings Quarterly Revenue |
|
Check Interpharm Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Interpharm Holdings' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 9.1 M or Total Revenue of 56.6 M, as well as many indicators such as Price To Sales Ratio of 0.0105, Dividend Yield of 0.16 or PTB Ratio of 0.0696. Interpharm financial statements analysis is a perfect complement when working with Interpharm Holdings Valuation or Volatility modules.
Interpharm | Revenue | Build AI portfolio with Interpharm Stock |
The Revenue trend for Interpharm Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Interpharm Holdings is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Interpharm Holdings' Revenue Growth Pattern
Below is the plot of the Total Revenue of Interpharm Holdings over the last few years. Total revenue comprises all receipts Interpharm Holdings generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Interpharm Holdings' Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Interpharm Holdings' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 75.59 M | 10 Years Trend |
|
Total Revenue |
| Timeline |
Interpharm Revenue Regression Statistics
| Arithmetic Mean | 74,921,279 | |
| Geometric Mean | 74,705,878 | |
| Coefficient Of Variation | 7.43 | |
| Mean Deviation | 2,508,689 | |
| Median | 75,587,000 | |
| Standard Deviation | 5,565,361 | |
| Sample Variance | 31T | |
| Range | 30.3M | |
| R-Value | (0.1) | |
| Mean Square Error | 32.7T | |
| R-Squared | 0.01 | |
| Significance | 0.71 | |
| Slope | (106,598) | |
| Total Sum of Squares | 495.6T |
Interpharm Revenue History
Other Fundumenentals of Interpharm Holdings
| Cost Of Revenue | ||
| Stock Based Compensation To Revenue | ||
| Sales General And Administrative To Revenue | ||
| Research And Ddevelopement To Revenue |
Interpharm Holdings Revenue component correlations
Click cells to compare fundamentals
About Interpharm Holdings Financial Statements
Investors use fundamental indicators, such as Interpharm Holdings' Revenue, to determine how well the company is positioned to perform in the future. Although Interpharm Holdings' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 86.9 M | 56.6 M | |
| Cost Of Revenue | 48.5 M | 32.4 M | |
| Research And Ddevelopement To Revenue | 0.23 | 0.24 | |
| Capex To Revenue | 0.10 | 0.10 | |
| Revenue Per Share | 1.33 | 1.27 | |
| Ebit Per Revenue | (0.14) | (0.16) |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Interpharm Holdings Correlation against competitors. For more detail on how to invest in Interpharm Stock please use our How to Invest in Interpharm Holdings guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is there potential for Pharmaceuticals market expansion? Will Interpharm introduce new products? Factors like these will boost the valuation of Interpharm Holdings. Market participants price Interpharm higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Interpharm Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Interpharm Holdings is measured differently than its book value, which is the value of Interpharm that is recorded on the company's balance sheet. Investors also form their own opinion of Interpharm Holdings' value that differs from its market value or its book value, called intrinsic value, which is Interpharm Holdings' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Interpharm Holdings' market value can be influenced by many factors that don't directly affect Interpharm Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Interpharm Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Interpharm Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Interpharm Holdings' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.